Second manifestations of ARTerial disease (SMART) study: rationale and design.
about
Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertensionExclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies.No Additional Prognostic Value of Genetic Information in the Prediction of Vascular Events after Cerebral Ischemia of Arterial Origin: The PROMISe Study.Uniform data collection in routine clinical practice in cardiovascular patients for optimal care, quality control and research: The Utrecht Cardiovascular Cohort.Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease.Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease.Testing bias in clinical databases: methodological considerations.Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study.Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics.Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].Distribution of cerebral blood flow in the caudate nucleus, lentiform nucleus and thalamus in patients with carotid artery stenosisInsulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART studyLevels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndromeRisk Factors for Lobar and Non-Lobar Intracerebral Hemorrhage in Patients with Vascular Disease.Reliability and agreement of adipose tissue fat fraction measurements with water-fat MRI in patients with manifest cardiovascular disease.Completeness of the circle of Willis and risk of ischemic stroke in patients without cerebrovascular disease.A gene-centric study of common carotid artery remodelling.Adjustment for continuous confounders: an example of how to prevent residual confoundingNon-invasive cardiac assessment in high risk patients (The GROUND study): rationale, objectives and design of a multi-center randomized controlled clinical trialNovel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus.The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART studyExtracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study.Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular diseasePersonalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.The relationship between metabolic syndrome and target organ damage in Ghanaian with stage-2 hypertension.Prevention of coronary artery disease: recent advances in the management of hypertension.The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus.Detection and characterization of small infarcts in the caudate nucleus on 7 Tesla MRI: The SMART-MR study.Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.Greater carotid intima media thickness at a younger age in HIV-infected patients compared with reference values for an uninfected cohort.Gender difference in long-term prognosis among patients with cardiovascular disease.Self-rated health status as a risk factor for future vascular events and mortality in patients with symptomatic and asymptomatic atherosclerotic disease: the SMART study.Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study.Prognostic value of the Rose questionnaire: a validation with future coronary events in the SMART study.Arterial spin-labeling MR imaging measurements of timing parameters in patients with a carotid artery occlusion.Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study.Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
P2860
Q24680384-9DCA36CD-DE26-422C-9FFF-88AC8D8B731CQ25256604-4D86A8B0-BA08-4F3A-96EF-9098626713F7Q30405365-B3C2A09C-DFC6-48FF-9746-13B517B69765Q31157319-3D7C9E51-60BE-4C28-9FF5-7577CBFEC055Q31157470-7208EBBE-7D54-4AE2-A61F-0DC46DA82197Q33825624-1C9889EF-7F89-4FBD-A9FC-1F058FEB8EEAQ33912082-6B7DF1D3-35C4-4E88-9C70-FAE3615A613DQ33950911-EB70A121-7428-41DB-90C1-EFE867ABD90AQ33983329-8083CE57-0A57-49A4-AAE8-38DDFB34821BQ34599557-51FA209E-61EB-44B0-A699-F718A6F21385Q34617030-478F069F-9103-4CA1-B780-E7B69887580BQ35712246-E09D2C2A-0117-45E7-8394-D77EA78E396FQ35773198-9C654D4F-4921-4D4B-8575-6CF637478C9EQ35833463-D795A3EE-D05D-4E2A-AD3C-89ABB1FE89B0Q35856219-9F6A6D93-385C-48F8-9E5C-2E41631BFDD9Q36289894-47C06DC0-2776-489E-9A8C-98177AEC9D87Q36612059-B420408C-079A-4CD9-BE58-31D18B8EB5A5Q36698638-9321889F-BB60-4D1D-A2DA-2AF9368D23B3Q36844204-97F8E08A-1900-4A30-AD62-EC052DD32CB2Q37076080-D1014481-3E30-4B65-B48D-F81275332FEDQ37107872-F78CB926-BDB9-4C28-8C17-95F63CA0EABDQ37112815-0597EDB4-008F-4B2D-ABE0-19898D808FCAQ37517034-1B896C06-C286-4F14-B572-2EC80129103DQ37568849-27C5C582-7D2D-46DF-9DEC-9BA24FB76ABBQ37580870-9DAE7BA5-182D-4E05-B2DB-0E3EFBC0618BQ37653959-38605CB4-9ADA-4CDB-B486-B84963F45AAEQ38075808-37994B26-0DFE-48BD-99F4-332E8E52945DQ38254322-863F2A43-1C73-475F-957A-877F3A3155DAQ38691727-4E7B661F-7CF5-48D0-8795-D2810BE6456FQ38860131-AE26806D-4960-465F-8CF0-74E13C52EE82Q39436973-FCFBBC58-D2DE-4E42-88F8-AB0448B5D276Q39540038-ACDC76CB-3A97-4C72-BB2D-AC535755D1A8Q39557778-53B23591-3CB8-4938-AFD5-489D888B2FB3Q39662636-8F95D512-9E52-4B41-859E-804CA2D3AAF5Q39729691-BF712856-8624-419F-866B-493C4DFE1B52Q39765892-E7AA1D95-4B14-410F-87EF-A09B00815232Q39857194-709C6707-442C-4333-BAB7-6317A47E0DE0Q39862966-69EF42E0-23CB-401B-8524-2EEC696B11D7Q40052463-15F865C7-08E4-41B3-AFA8-9C72ECF89774Q40124148-5513830B-9AE4-4029-A106-1665B89B56A8
P2860
Second manifestations of ARTerial disease (SMART) study: rationale and design.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Second manifestations of ARTerial disease (SMART) study: rationale and design.
@en
type
label
Second manifestations of ARTerial disease (SMART) study: rationale and design.
@en
prefLabel
Second manifestations of ARTerial disease (SMART) study: rationale and design.
@en
P2093
P356
P1476
Second manifestations of ARTerial disease (SMART) study: rationale and design.
@en
P2093
Grobbee DE
van de Laak MF
van der Graaf Y
P2888
P304
P356
10.1023/A:1007621514757
P577
1999-10-01T00:00:00Z
P6179
1026921496